Press release
Carlyle Makes Strategic Growth Investment in TriNetX; Acquires Majority Stake in Leading Global Health Research Network
Investment Will Accelerate Development of New Clinical Research Capabilities for Healthcare Organizations and Life Sciences Customers, With the Aim of
About this update from The Carlyle Group Inc.
[{"type":"text","content":"Investment Will Accelerate Development of New Clinical Research Capabilities for Healthcare Organizations and Life Sciences Customers, With the Aim of Capitalizing on Both Organic and Inorganic Growth Opportunities\n\n\nNEW YORK and CAMBRIDGE, Mass., Sept. 21, 2020 /PRNewswire/ -- TriNetX (www.trinetx.com), the leading global health research network optimizing clinical research to bring new therapies to market faster, today announced global investment firm The Carlyle Group (NASDAQ: CG) has made a strategic growth investment and will acquire a majority stake in the Company. Terms of the transaction were not disclosed. \n\n \n \n \n \n \n \n\n \nSince its founding in 2013, TriNetX has built the largest global network of research hospitals and academic institutions, top biotech and pharmaceutical companies, contract research organizations (CROs) and other specialty data partners. TriNetX is powered by an impressive network of 170 healthcare organizations in 30 countries and used by more than 40 life sciences organizations including 15 of the world's top 20 pharmaceutical companies.\n\"Our goal is to be on the desktop of every healthcare researcher in the world,\" said Gadi Lachman, CEO of TriNetX. \"To accomplish this we need to continue to develop solutions to support clinical research at our healthcare organizations and bring more global data and technologies such as AI, machine learning and analytics to researchers so that they can ask more questions and generate more real-world evidence. Carlyle's investment accelerates our growth plans and will shorten the time it takes to turn our vision into reality.\" \nTriNetX enables researchers to apply a data-driven approach to health research by providing web-based, on-demand access to harmonized global electronic health record (EHR) and claims data with a suite of highly intuitive analytics. TriNetX is utilized in all parts of the drug development cycle, including protocol design and feasibility, site selection and patient identification for clinical trials, as well as serving clinical research for drugs already in the market to help researchers understand efficacy, risks and other market dynamics and to generate real-world evidence (RWE) to support hypothesis and decision making, in real-time. \nThe longitudinal clinical and claims data representing over 400 million patients availab...